Amgen announces $1B manufacturing expansion in North Carolina

Amgen (AMGN) announced a $1B expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company’s total planned investment in Holly Springs to more than $1.5B, building on its previously announced $550M commitment. The $1B facility will incorporate cutting-edge technologies and sustainable practices, aligning with Amgen’s commitment to environmental stewardship and manufacturing excellence. In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting a robust biomanufacturing hub.